This is an open-label, four-arm, randomized, controlled clinical study designed to evaluate the efficacy and safety of a structured Weight Management Program (WMP) in overweight and obese adults with a body mass index (BMI) ≥ 23 kg/m² (Asian Indian ethnicity cut-off). A total of 140 subjects will be enrolled and randomized equally into four arms: one control arm and three intervention arms with varying levels of nutritional intervention. The Weight Management Program comprises three sequential phases: a pre-engagement gut-reset phase (10 days), an intensive intervention phase (30 days), and a maintenance phase (60 days). The intervention arms will receive combinations of meal replacements, protein supplements, fiber supplements, probiotics, and multivitamin-multimineral supplements, along with nutritional and behavioral counseling, calorie-deficit diet plans, and prescribed physical activity. The control arm will follow a free-living lifestyle without intervention. The primary efficacy outcome is the proportion of subjects demonstrating a reduction in body weight and/or BMI from baseline to the end of the intensive phase. Secondary outcomes include changes in body weight and BMI at the end of the maintenance phase, maintenance of weight loss, changes in body composition, waist circumference, waist-hip ratio, lipid profile, metabolic parameters, physical activity, quality of life, and safety outcomes including adverse events. The study aims to generate evidence on the effectiveness and safety of a holistic, lifestyle-based weight management program incorporating nutritional supplementation, dietary modification, physical activity, and behavioral support in overweight and obese individuals.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
140
I. Investigational Product Morning- PRP-02 (1 scoop) + AND-16 Afternoon- PRP-02 (1 scoop) Night-PRP-02 (1 scoop) + FBR-18 (1 scoop) +PRO-19 II. Nutritional+ Behavioral counselling (Audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60-minute exercise 5 days a week or 150-300-minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)
I. Investigational Product - Replace breakfast with BDK-01+PRP-02 (2 scoops) Afternoon - as per diet plan Night- FBR- 18 (1 scoop) +PRO- 19 II. Nutritional + Behavioral counselling (Daily audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60 minute exercise 5 days a week or 150 - 300 minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)
I. Investigational Product Replace breakfast with BDK-01+PRP-02 (2 scoops) Afternoon-BDK-01+ Skimmed milk powder (Only during intensive phase, in maintenance phase switch to 1 meal replacement only) Night-FBR- 18+PRO- 19 II. Nutritional + Behavioral counselling (Daily audio clips will be shared) III. Calorie deficit Diet Plan IV. Physical exercise: Moderate exercise - 30-60 minute exercise 5 days a week or 150-300 minute exercise per week (Exercise: brisk walking, aerobic exercise, jogging, cycling etc)
Sapthagiri Institute of Medical Sciences & Research Centre
Bangalore, Karnataka, India
Change in Body Weight
To assess the number and percentage of subjects demonstrating a reduction in body weight from baseline to the end of the intensive phase across intervention and control arms.
Time frame: Baseline (Day 1) to end of intensive phase (Day 30)
Change in BMI During Maintenance Phase
To assess the number and percentage of subjects demonstrating a reduction in BMI from baseline to the end of the maintenance phase, and the proportion of subjects maintaining weight loss achieved during the intensive phase.
Time frame: Baseline (Day 1) to end of study (Day 90)
Change in Body Fat Percentage
To evaluate the change in body fat percentage from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.
Time frame: Baseline (Day 1) to end of study (Day 90)
Change in Waist Circumference
To assess the change in waist circumference from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to end of study (Day 90)
Change in Total Cholesterol
To evaluate the change in total cholesterol levels from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to end of study (Day 90)
Change in Quality of Life
Change from baseline in quality of life assessed using the World Health Organization Quality of Life - Brief Version (WHOQOL-BREF) questionnaire from baseline to the end of the study. The WHOQOL-BREF is a validated 26-item questionnaire that assesses four domains: physical health, psychological health, social relationships, and environment. Domain scores are transformed to a 0-100 scale, where higher scores indicate better quality of life.
Time frame: Baseline (Day 1) to end of study (Day 90)
Incidence of Adverse Events
To assess the incidence, severity, and relationship of adverse events reported during the study period across all study arms.
Time frame: From baseline (Day 1) to end of study (Day 90)
Change in Muscle Mass
To evaluate the change in muscle mass from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in Fat-Free Mass
To evaluate the change in fat-free mass from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in Visceral Fat Level
To evaluate the change in visceral fat level from baseline to end of study using a validated body composition analyzer, and to compare the mean change between study arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in Waist-to-Hip Ratio
To assess the change in waist-to-hip ratio from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in Skinfold Thickness
To assess the change in skinfold thickness from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in Triglycerides
To evaluate the change in triglyceride levels from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in High-Density Lipoprotein (HDL) Cholesterol
To evaluate the change in HDL cholesterol levels from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in Low-Density Lipoprotein (LDL) Cholesterol
To evaluate the change in LDL cholesterol levels from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in Fasting Blood Glucose
To evaluate the change in fasting blood glucose levels from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in Glycated Hemoglobin (HbA1c)
To evaluate the change in HbA1c levels from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
Change in Serum Insulin
To evaluate the change in fasting serum insulin levels from baseline to the end of the study and to compare the mean change between intervention and control arms.
Time frame: Baseline (Day 1) to End of Study (Day 90)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.